Missouri is currently home to 1898 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with bud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Washington University-School of Medicine /ID# 262943, Saint Louis, Missouri
Conditions: Solid Tumors
Register for Updates
Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
NCT04919018
Recruiting
Though common, morbidities related to upper airway disease in primary ciliary dyskinesia (PCD) and primary immunodeficiencies (PID) have not been fully characterized. These conditions can be difficult to distinguish due to their overlapping phenotypes. The sinonasal and middle ear features are often identified as most problematic by patients and their families, and optimal, highly effective treatment regimens have not been established. The main objective of this project is to characterize and co... Read More
Gender:
ALL
Ages:
Between 5 years and 45 years
Trial Updated:
10/07/2024
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Primary Ciliary Dyskinesia, Kartagener Syndrome, Primary Immune Deficiency
Register for Updates
Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
NCT04702243
Recruiting
The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
Gender:
ALL
Ages:
Between 5 years and 45 years
Trial Updated:
10/07/2024
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome
Register for Updates
Targeted Lifestyle Change Group Prenatal Care
NCT04090307
Recruiting
To conduct a randomized trial to determine the effect of Targeted Lifestyle Change Group Prenatal Care (TLC) on maternal and neonatal outcomes in women at high risk for developing gestational diabetes mellitus (GDM).
Gender:
FEMALE
Ages:
13 years and above
Trial Updated:
10/07/2024
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Pregnancy, Gestational Diabetes
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Saint Louis University, Saint Louis, Missouri
Conditions: Giant Cell Tumor of Bone
Register for Updates
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
NCT05618301
Recruiting
Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation. However, effective HSC-based gene therapy depends on collecting sufficient HSCs to generate the therapeutic product, and currently available mobilization regimens carry unacceptable risk for patients with SCD or do not reliably yield optimal numbers of HSCs for gene therapy. The investigato... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Sickle Cell Disease
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - 017-820F, Kansas City, Missouri
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
NCT03988283
Recruiting
The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with brain tumors that have returned or have been resistant to treatment.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
10/04/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Pediatric Recurrent Brain Tumor
Register for Updates
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT02910557
Recruiting
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Gender:
ALL
Ages:
All
Trial Updated:
10/04/2024
Locations: Jefferson City Medical Group PC, Jefferson City, Missouri
Conditions: Melanoma, Herpetic Infection
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: University of Missouri, Columbia, Missouri
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
Add-on Reparixin in Adult Patients With ARDS
NCT05496868
Recruiting
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: University of Missouri Health Care, Columbia, Missouri
Conditions: Acute Respiratory Distress Syndrome, Adult
Register for Updates
PAL to Improve Oral Feeding for Infants With Chronic Lung Disease
NCT05446389
Recruiting
The purpose of this study is to investigate the effects of the Pacifier Activated Lullaby (PAL) intervention on the transition to oral feeding for preterm infants with chronic lung disease and respiratory distress syndrome that require non-invasive respiratory support at 34 weeks PMA. This study will utilize a clinical trial design. Participants will be randomized into two groups. One group will receive the PAL intervention, the other group serving as a no contact control. Participants will be m... Read More
Gender:
ALL
Ages:
Between 1 day and 33 weeks
Trial Updated:
10/03/2024
Locations: University of Missouri Healthcare, Columbia, Missouri
Conditions: Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia, Preterm Birth
Register for Updates